Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Non-cytomembrane PD-L1: An atypical target for cancer
Honggang Ying, Xiaozhen Zhang, Yi Duan, et al.
Pharmacological Research (2021) Vol. 170, pp. 105741-105741
Open Access | Times Cited: 32

Showing 1-25 of 32 citing articles:

Regulatory mechanisms of PD-1/PD-L1 in cancers
Xin Lin, Kuan Kang, Pan Chen, et al.
Molecular Cancer (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 111
Biological Characteristics and Clinical Significance of Soluble PD-1/PD-L1 and Exosomal PD-L1 in Cancer
Mengke Niu, Yiming Liu, Ming Yi, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 92
Targeting myeloid-derived suppressor cells in tumor immunotherapy: Current, future and beyond
Yang Zhao, Junfeng Du, Xiaofei Shen
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 43
Challenges Coexist with Opportunities: Spatial Heterogeneity Expression of PD‐L1 in Cancer Therapy
Yazhen Wang, Zhou Yang, Lianyi Yang, et al.
Advanced Science (2023) Vol. 11, Iss. 1
Open Access | Times Cited: 23
Reducing PD-L1 Expression by Degraders and Downregulators as a Novel Strategy to Target the PD-1/PD-L1 Pathway
Zhijie Wang, L. Yuan, Xiaotong Liao, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 8, pp. 6027-6043
Closed Access | Times Cited: 8
FBW7-mediated ubiquitination and destruction of PD-1 protein primes sensitivity to anti-PD-1 immunotherapy in non-small cell lung cancer
Jiaxin Liu, Lingyun Wei, Nan Hu, et al.
Journal for ImmunoTherapy of Cancer (2022) Vol. 10, Iss. 9, pp. e005116-e005116
Open Access | Times Cited: 37
PD-1/PD-L1 axis in organ fibrosis
Youliang Zhao, Yaqian Qu, Changfu Hao, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 21
Tumour cell-expressed PD-L1 reprograms lipid metabolism via EGFR/ITGB4/SREBP1c signalling in liver cancer
Man Zhao, Hongfeng Yuan, Guang Yang, et al.
JHEP Reports (2024) Vol. 6, Iss. 4, pp. 101009-101009
Open Access | Times Cited: 7
Recent advances and mechanisms of action of PD-L1 degraders as potential therapeutic agents
Feng Zhang, Ruiya Jiang, Shishi Sun, et al.
European Journal of Medicinal Chemistry (2024) Vol. 268, pp. 116267-116267
Closed Access | Times Cited: 6
Late relapse after CAR-T cell therapy for adult patients with hematologic malignancies: A definite evidence from systematic review and meta-analysis on individual data
Alessia Zinzi, Mario Gaio, Valerio Liguori, et al.
Pharmacological Research (2023) Vol. 190, pp. 106742-106742
Open Access | Times Cited: 13
A splicing isoform of PD-1 promotes tumor progression as a potential immune checkpoint
Xuetong Wang, Tongfeng Liu, Yifei Li, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 5
Prognostic value of PD-1, PD-L1 and PD-L2 deserves attention in head and neck cancer
Siqing Jiang, Xin Li, Lihua Huang, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 19
Establishment and clinical value of a circulating tumor cell system based on a multi-site immune lipid magnetic sphere technique in laryngopharyngeal head and neck tumors
Wei Chen, Qin Lin, Desheng Wang, et al.
American Journal of Cancer Research (2025) Vol. 15, Iss. 1, pp. 19-31
Closed Access
Soluble immune checkpoint molecules: mechanism of formation, function, role in malignant neoplasms
Glazanova Tv, Irina Pavlovа, E. V. Kuzmich, et al.
Medical Immunology (Russia) (2025) Vol. 27, Iss. 1, pp. 21-34
Open Access
Developing a risk score using liquid biopsy biomarkers for selecting Immunotherapy responders and stratifying disease progression risk in metastatic melanoma patients
Amalia Azzariti, Simona De Summa, Tommaso Maria Marvulli, et al.
Journal of Experimental & Clinical Cancer Research (2025) Vol. 44, Iss. 1
Open Access
Assessing the Clinical Relevance of Soluble PD-1 and PD-L1: A Multi-Cohort Study Across Diverse Tumor Types and Prognostic Implications
Nikolay E. Kushlinskii, О. В. Ковалева, Alexei Gratchev, et al.
Biomedicines (2025) Vol. 13, Iss. 2, pp. 500-500
Open Access
Hsa-miR-4277 Decelerates the Metabolism or Clearance of Sorafenib in HCC Cells and Enhances the Sensitivity of HCC Cells to Sorafenib by Targeting cyp3a4
Xi He, Huiwei Sun, Qiyu Jiang, et al.
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 20
Exploring the potential of exosomes in diagnosis and drug delivery for pancreatic ductal adenocarcinoma
Biaoming Xu, Yu Chen, Mingjing Peng, et al.
International Journal of Cancer (2022) Vol. 152, Iss. 2, pp. 110-122
Open Access | Times Cited: 11
PD-L1’s Role in Preventing Alloreactive T Cell Responses Following Hematopoietic and Organ Transplant
Shane Handelsman, Juliana Overbey, Kevin Chen, et al.
Cells (2023) Vol. 12, Iss. 12, pp. 1609-1609
Open Access | Times Cited: 6
Design, Synthesis, and Evaluation of 8-(o-Tolyl)quinazoline Derivatives as Small-Molecule PD-1/PD-L1 Antagonists
Xingye Wu, He Li, Han Liu, et al.
ACS Medicinal Chemistry Letters (2024) Vol. 15, Iss. 4, pp. 518-523
Closed Access | Times Cited: 2
Transcription Factor ETV4 Activates AURKA to Promote PD-L1 Expression and Mediate Immune Escape in Lung Adenocarcinoma
Ping Yang, Shangxiang He, Ling Ye, et al.
International Archives of Allergy and Immunology (2024) Vol. 185, Iss. 9, pp. 910-920
Closed Access | Times Cited: 2
Expression, regulation, and function of PD-L1 on non-tumor cells in the tumor microenvironment
Lingrong Hu, Chengliang Sun, Kai Yuan, et al.
Drug Discovery Today (2024), pp. 104181-104181
Closed Access | Times Cited: 2
Sinensetin inhibits the movement ability and tumor immune microenvironment of non‐small cell lung cancer through the inactivation of AKT/β‐catenin axis
Zhenliang Shi, Yimeng Shen, Xin Liu, et al.
Journal of Biochemical and Molecular Toxicology (2024) Vol. 38, Iss. 11
Closed Access | Times Cited: 2
Boningmycin induces AMPK-mediated endoplasmic reticulum-associated degradation of PD-L1 protein in human cancer cells
Juan Zhang, Jincai Wang, Yue Shang, et al.
International Immunopharmacology (2023) Vol. 124, pp. 110905-110905
Closed Access | Times Cited: 5
Design, synthesis, anti-tumor activity and mechanism of novel PROTACs as degraders of PD-L1 and inhibitors of PD-1/PD-L1 interaction
Feng Zhang, Qimeng Yu, Caiyun Wu, et al.
Bioorganic & Medicinal Chemistry (2024) Vol. 111, pp. 117867-117867
Closed Access | Times Cited: 1
Page 1 - Next Page

Scroll to top